Norgesic Forte Tablet, Multilayer
NDC Package 50991-999-06

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Norgesic Forte (orphenadrine citrate, aspirin and caffeine) tablets is norgesic Forte 50 mg/770mg/60 mg Tablets are indicated in:Symptomatic relief of mild to moderate pain of acute musculoskeletal disorders.The orphenadrine component is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. This formulation utilizes a tablet, multilayer delivery system. Marketed by Poly Pharmaceuticals, Inc., this product is identified by NDC 50991-999 and is authorized under FDA application ANDA075141.

Identification & Billing

NDC Package Code
50991-999-06
Package Description
6 TABLET, MULTILAYER in 1 CARTON
Product Code
50991-999
11-Digit Billing Format
50991099906
RxNorm Crosswalk
  • RxCUI: 994535 - orphenadrine citrate 50 MG / aspirin 770 MG / caffeine 60 MG Oral Tablet
  • RxCUI: 994535 - aspirin 770 MG / caffeine 60 MG / orphenadrine citrate 50 MG Oral Tablet
  • RxCUI: 994535 - ASA 770 MG / caffeine 60 MG / orphenadrine citrate 50 MG Oral Tablet
  • RxCUI: 994537 - Norgesic Forte 50 MG / 770 MG / 60 MG Oral Tablet
  • RxCUI: 994537 - aspirin 770 MG / caffeine 60 MG / orphenadrine citrate 50 MG Oral Tablet [Norgesic]

Clinical Specifications

Proprietary Name
Norgesic Forte
Non-Proprietary Name
Orphenadrine Citrate, Aspirin And Caffeine
Substance Name
Aspirin; Caffeine; Orphenadrine Citrate
Dosage Form
Tablet, Multilayer - A solid dosage form containing medicinal substances that have been compressed to form a multiple-layered tablet or a tablet-within-a-tablet, the inner tablet being the core and the outer portion being the shell.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Pharmacologic Class
Usage Information
Norgesic Forte 50 mg/770mg/60 mg Tablets are indicated in:Symptomatic relief of mild to moderate pain of acute musculoskeletal disorders.The orphenadrine component is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. The mode of action of orphenadrine has not been clearly identified, but may be related to its analgesic properties. Norgesic Forte Tablets do not directly relax tense skeletal muscles in man.

Regulatory & Marketing

Labeler Name
Poly Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA075141
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
04-01-2019
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (50991-999). Click a package code to view its specific billing and regulatory data.

50991-999-60
60 TABLET, MULTILAYER in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 50991-999-06 identifies a specific commercial package of 6 tablet, multilayer in 1 carton of Norgesic Forte, a human prescription drug labeled by Poly Pharmaceuticals, Inc.. This tablet, multilayer is formulated for oral use and contains aspirin; caffeine; orphenadrine citrate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Poly Pharmaceuticals, Inc. on April 01, 2019. The current certification is valid through December 31, 2026.

How is this Poly Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 50991099906. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
50991-999-06
11-Digit CMS (5-4-2)
50991-0999-06

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.